Celgene (CELG) Tops Q1 EPS by 9c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Celgene Reports First Quarter 2018 Operating and Financial Results
May 4, 2018 7:30 AM EDTQ1:18 total net product sales of $3,531 million, increased 20% Y/Y
Raising full-year 2018 revenue guidance to high end of previous range
Completion of Juno Therapeutics & Impact Biomedicines acquisitions will strengthen pipeline and capabilities
Submission of NDA and MAA for ozanimod in relapsing multiple sclerosis expected in Q1:19
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $3,531 million for the first quarter of 2018, a 20 percent increase from the same period in 2017. Celgene reported first quarter 2018 total... More
